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IncreasedROS(cellularreactiveoxygenspecies)arecharacteristicofbothﬁbrosisandtumourdevelopment.ROSinducethetrans-
diﬀerentiation to myoﬁbroblasts, the activated form of ﬁbroblasts able to promote cancer progression. Here, we report the role of
ROS produced in response to dysfunctions of mitochondrial complex I, in ﬁbroblast activation and in tumour progression. We
studied human ﬁbroblasts with mitochondrial dysfunctions of complex I, leading to hyperproduction of ROS. We demonstrated
that ROS level produced by the mutated ﬁbroblasts correlates with their activation. The increase of ROS in these cells provides a
greater ability to remodel the extracellular matrix leading to an increased motility and invasiveness. Furthermore, we evidentiated
that in hypoxic conditions these ﬁbroblasts cause HIF-1α stabilization and promote a proinvasive phenotype of human melanoma
cells through secretion of cytokines. These data suggest a possible role of deregulated mitochondrial ROS production in ﬁbrosis
evolution as well as in cancer progression and invasion.
1.Introduction
Mitochondrial-produced ROS have been recently involved
in metastatic dissemination of cancer cells, as shown by
Ishikawa et al. These authors described how replacing the
endogenous mitochondrial DNA in a weakly metastatic
tumour cell line with mitochondrial DNA from a highly
metastatic cell line enhanced tumour progression through
increased production of ROS and HIF-1α stabilization [1].
Recent studies demonstrate that tumour growth does
not depend only on malignant cancer cells themselves but
also on the surrounding tumour stroma. Indeed, tumour
progression, growth, and spread is strictly dependent on
angiogenesis and on cytokines and growth factors secreted
by microenvironmental cells [2]. In this context, evidence
is increasing that CAFs (cancer-associated ﬁbroblasts) are
key determinants in the malignant progression of can-
cer [3]. These ﬁbroblasts, also commonly referred to as
myoﬁbroblasts, are the diﬀerentiated form of ﬁbroblast that
have acquired contractile and secretory characteristics [4].
They have been initially identiﬁed during wound healing
[5], but are also present in the reactive tumour stroma,
promoting tumour growth and progression [6]. Their role
is linked to extracellular matrix deposition and secretion of
MMPs (matrix metalloproteinases). Furthermore, activated
ﬁbroblasts inﬂuence cancer cells through the secretion of
growth factors and are able to mediate EMT (epithelial mes-
enchymaltransition)andstemnessoftumorcellsthemselves,
supporting their progression and the metastatic process.
Transdiﬀerentiation to myoﬁbroblast is dependent on both
exposure to MMPs and increased level of cellular ROS
[7, 8]. Increased cellular ROS are characteristic of both
ﬁbrosis and malignancy. We have recently demonstrated
that CAFs induce EMT of prostate cancer cells through a
proinﬂammatory pathway involving COX-2 (cycloxygenase-
2),NF-κB(nuclearfact or -κB),andHIF-1α[9].Thesecretion2 Journal of Signal Transduction
of MMPs by CAFs induces a release of ROS in prostate
carcinoma cells, which is mandatory for EMT, stemness, and
dissemination of metastatic cells.
The aim of the present work is to assess the role of
ROS produced in response to mitochondrial dysfunctions in
ﬁbroblast activation and in tumour progression.
Analysis of human ﬁbroblasts with genetic dysfunctions
of mitochondrial complex I show that ROS level produced
by these ﬁbroblasts correlate with their activation, leading
to enhanced motility and invasiveness. Furthermore, in
hypoxic conditions, we evidentiated that ROS generated by
mitochondrial mutations promote a proinvasive phenotype
of melanoma cells though HIF-1α stabilization and growth
factor secretion.
2. Results
2.1. ROS Produced by Fibroblasts Carrying Mitochondrial
Disfunctions Induce Transdiﬀerentiation to Myoﬁbroblasts.
Our interest is to assess the role of mitochondrial oxidative
stress for stromal ﬁbroblast activation during tumour pro-
gression. To this end we used human ﬁbroblasts carrying
mitochondrial dysfunctions of complex I. In particular,
ﬁbroblasts mutated in the nuclear NDUFS1 gene encoding
for the 75kDa-FeS protein (NDUFS1 Q522K and NDUFS1
R557X/T595A) of mitochondrial complex I, ﬁbroblasts
mutated in the nuclear NDUFS4 gene encoding for the
18kDa subunit (NDUFS4 W15X) of mitochondrial complex
I, and ﬁbroblasts mutated in the nuclear PINK1 gene encod-
ing for the PTEN induced Ser/Thr putative kinase1 localized
in mitochondria (PINK W437X), in the same patient this
mutation coexists with two homoplasmic mtDNA missense
mutations in the ND5 and ND6 genes coding for two
subunits of complex I [10, 11]. As control we used neonatal
human dermal ﬁbroblasts (HFY). Previously, it has been
shown that mutation in NDUSF4 gene results in com-
plete suppression of the NADH-ubiquinone oxidoreductase
activity of complex I, without any ROS accumulation [12].
The Q522K mutation in the NDUFS1 gene results in a
marked, but not complete, suppression of complex I activity
with large accumulation of H2O2 and intramitochondrial
superoxide ion [12]. Furthermore, it has been shown that
the coexistence of the ND5 and ND6 mutations with the
PINK1 mutation, contributes to enhanced ROS production
bycomplexIandtoadecreaseintheKmforNADH[11,13].
We ﬁrst detected the superoxide ion production by ﬂow
cytometer analysis and confocal microscopy analysis using
Mitosox as a redox-sensitive probe. As shown in Figures 1(a)
and 1(b), mutations in NDUFS1 genes and in PINK gene are
associated with superoxide ion accumulation while NDUFS4
gene mutation aﬀects only marginally ROS production in
a g r e e m e n tw i t hp r e v i o u sd a t a[ 12]. Recently, it has been
demonstrated that the oxidative stress in the tumour stroma
promotes the conversion of ﬁbroblasts into myoﬁbroblasts,
a contractile and secretory form of ﬁbroblasts [7]. To
this purpose we analysed whether also ROS produced by
mitochondrial disfunctions could aﬀect the diﬀerentiation
process of ﬁbroblasts. We analysed the expression level
of α-SMA (α-smooth muscle actin), a typical marker of
myoﬁbroblast diﬀerentiation, by western blot and confocal
microscopy analyses (Figures 1(c) and 1(d)). The level of α-
SMA in control and mutated ﬁbroblasts correlates with ROS
production, in particular, in ﬁbroblasts carrying mutations
in the NDUFS1 gene (Q522K and R557X/T595A) and in the
nuclear PINK gene (W437X) α-SMA is organized in stress
ﬁbers,therebyconferringtothediﬀerentiatedmyoﬁbroblasts
a strong contractile activity. Altogether, these data show that
ROS produced by ﬁbroblasts carrying mitochondrial genetic
disfunctions correlates with their activation.
2.2. Mitochondrial ROS Production Induces an Increase in the
Migration and Invasion Abilities of Myoﬁbroblasts. During
the conversion of ﬁbroblasts into myoﬁbroblasts, these cells
acquireclear contractileand motile properties. To investigate
whether ﬁbroblasts carrying mitochondrial disfunctions and
showing increased ROS level have modiﬁed their behaviour,
we evaluated the migration and invasion abilities of these
cells by Boyden assays. As shown in Figures 2(a) and 2(b),
mutations in NDUFS1 gene (Q522K and R557X/T595A) and
in the nuclear PINK gene (W437X) increase both migration
and invasion of ﬁbroblasts while mutations in NDUFS4 gene
do not aﬀect the contractile properties of cells, in agreement
with their ROS production and α-SMA expression. Hence,
we proposed that high mitochondrial generation of ROS
convertsﬁbroblastsintomyoﬁbroblasts,theiractivatedform,
causing an increase in the invasive and migratory abilities of
these cells.
2.3. Hypoxic ROS Production in Mutated Fibroblasts Is Associ-
ated with HIF-1α Stabilization and Growth Factor Expression.
Hypoxic conditions are able to induce a deregulation in
mitochondrial ROS production, which control a variety of
hypoxic responses, including the activation of HIF-1α tran-
scription factor [14–16]. To this end, we analysed ROS pro-
duction after culturing ﬁbroblasts under hypoxic conditions
(1% O2). As shown in Figure 3(a), genetic mitochondrial
disfunctions result in increased ROS production in hypoxic
conditions. This eﬀect is mainly evident for ﬁbroblasts
carrying mutations in nuclear PINK1 gene. Noticeable,
also ﬁbroblasts mutated in NDUFS4 gene show high level
of ROS in hypoxic conditions. In agreement, in hypoxic
conditions, all mutated ﬁbroblasts show an increase of
HIF-1α level (Figure 3(b)). Previous results from other
laboratories indicated that the activated stroma secretes large
amounts of VEGF-A (vascular endothelial growth factor-A),
SDF1 (stromal cell-derived factor-1) and HGF (hepatocyte
growthfactor)leadingtoasigniﬁcantincreaseintheinvasive
capacity of surrounding tumor cells [17–19]. In order to
verify whether the increased ROS production in mutated
ﬁbroblasts correlates with a raise of these soluble growth
factorsandcytokines,weperformedareal-timePCRanalysis
to quantify VEGF-A, SDF1, and HGF transcripts. As shown
in Figures 4(a) and 4(c) mutated ﬁbroblasts cultured in
hypoxicconditionshavehigherleveloftranscriptsforVEGF-
A, SDF1, and HGF, acknowledged factors for the modulation
of the response of tumour cells to activated ﬁbroblasts.Journal of Signal Transduction 3
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Figure 1: Oxygen superoxide level and α-SMA in ﬁbroblasts carrying mitochondrial dysfunctions of complex I. (a) Flowcytometer analysis
of O2
•− level. Control ﬁbroblasts (HFY) and ﬁbroblasts carrying mutations in NDUFS1 gene (Q522K and R557X/T595A), in NDUFS4 gene
(W15X), and in the nuclear PINK gene (W437X) were cultured for 48 hours in low glucose medium and then incubated with 5mM Mitosox
for 10 minutes at 37◦C for detection of oxygen superoxide. A ﬂowcytometer analysis is then performed. The results are representative of
ﬁve experiments with similar results. ∗P<0.005 mutated ﬁbroblasts versus control ﬁbroblasts. (b) Fibroblasts seeded on glass coverslips
are treated as in (a) and a confocal microscopy analysis is performed. (c) Analysis of α-SMA expression in control ﬁbroblasts (HFY) and
ﬁbroblasts carrying mutations. Lysates of cells were subjected to α-SMA immunoblot analysis. An antiactin immunoblot was performed for
normalization. (d) Analysis of α-SMA expression in control ﬁbroblasts (HFY) and ﬁbroblasts carrying mutations seeded on glass coverslips
by confocal microscopy analysis.
2.4. The Conditioned Media of Mutated Fibroblasts Promotes
Melanoma Cells Invasiveness. Recently, it has been demon-
strated that high levels of mitochondrial ROS produced by
cancer cells are linked to enhanced metastatic potential [1].
To this end we decided to investigate whether mitochondrial
ROS derived from stromal components could, as well,
inﬂuence the behavior of tumor cells. Thus, we analysed
the ability of media from mutated ﬁbroblasts cultured
under hypoxic conditions to promote metastatic potential of
cancer cells, using A375 cells, derived from human primary
melanoma. As shown in Figure 5(a), left, while there are
no diﬀerences in A375 human melanoma cells invasiveness
when cultured with media from ﬁbroblasts grown in nor-
moxic condition, media from mutated ﬁbroblasts cultured
in hypoxic conditions cause an increase in A375 human
melanoma cells invasiveness as examined by Boyden cell
invasion assay (Figure 5(a), right).
To verify that the eﬀect exerted by media from mutated
ﬁbroblasts on the invasiveness of melanoma cells are eﬀec-
tively due to their ROS production and HIF-1α stabilization,
we analyzed HIF-1α level and melanoma cell invasion in the
presence of NAC (N-acetyl cysteine), a ROS scavenger. As
shown in Figures 5(b) and 5(c), NAC treatment blocks HIF-
1α accumulation and reverts the increase of invasiveness of
A375 treated with media from mutated ﬁbroblasts cultured
in hypoxic conditions. Hence, this evidence underlines the4 Journal of Signal Transduction
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(a) Boyden cell migration assays of ﬁbroblasts carrying mitochondrial
dysfunctions of complex I. 15×103 ﬁbroblasts, after 24 hours of
serum starvation, were seeded into the upper compartment of Boyden
chamber. Cells were allowed to migrate through the ﬁlter toward the
lower compartment ﬁlled with complete medium. Cell invasion was
evaluated after Diﬀ-Quick staining by counting cell in six randomly
chosen ﬁelds. The results are representative of four experiments with
similar results
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(b) Boyden cell invasion assays of ﬁbroblasts carrying mitochon-
drial dysfunctions of complex I. Cells were treated as in (a). Cells
were allowed to migrate through the ﬁlter coated with Matrigel
toward the lower compartment ﬁlled with complete medium. Cell
invasion was evaluated after Diﬀ-Quick staining by counting cell
insixrandomlychosenﬁelds.Theresultsarerepresentativeoffour
experiments with similar results. ∗P<0.005 mutated ﬁbroblasts
versus control ﬁbroblasts
Figure 2: Mutations in NDUFS1 genes (Q522K and R557X/T595A) and in the nuclear PINK gene (W437X) increase ﬁbroblasts migration
and invasion.
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Figure 3: Mutated ﬁbroblasts induce HIF-1α stabilization in hypoxic conditions.Journal of Signal Transduction 5
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Figure 4: mRNA levels of VEGF-A, SDF-1, and HGF secreted by ﬁbroblasts cultured in hypoxic condition. (a–c) Quantitative real-time
reverse transcription PCR of RNA extracted from ﬁbroblasts cultured for 24 hours in low glucose serum-free medium in hypoxic conditions
using primers for human VEGF-A (a),S D F - 1(b), and HGF (c) and GAPDH gene. Results were normalized ﬁrst to GADPH expression levels
and then displayed relative to level in HFY cells. Data are representative of three independent experiments. ∗P<0.005 mutated ﬁbroblasts
versus control ﬁbroblasts.
involvement of mitochondrial ROS production in regulating
the aggressiveness of melanoma cells, likely modulating the
delivery of key cytokines able to aﬀect cancer cell invasive-
ness.
3. Discussion
Datareportedinthisstudyclearlyunderscorethecentralrole
of mitochondrial ROS in the transdiﬀerentiation of ﬁbrob-
lasts and in the stimulation of a pro-invasive phenotype of
melanoma tumour cells.
Recent data unlighted that tumour microenvironment
has a key role for the development of a variety of cancers
promoting both tumour growth and metastatic dissemina-
tion. CAFs are the most common type of cells found in
the reactive stroma of several human carcinomas. These
activated ﬁbroblasts express α-SMA, leading to the term
“myoﬁbroblasts,” inﬂuence ECM turnover synthesizing both
components of ECM itself and ECM-degrading enzymes,
release a large amount of cytokines aﬀecting cancer cells
progress towards an aggressive phenotype. The origin of
myoﬁbroblasts are not fully understood. In culture the
transdiﬀerentiation of ﬁbroblasts to myoﬁbroblasts can be
achieved by treatment with TGFβ (transforming growth
factor β)[ 20], suggesting that similar pathways might be
responsible for generation of myoﬁbroblasts in tumours.
Besides, emerging evidence indicates that also EMT, involv-
ing normal epithelial cells adjacent to the tumour, is a
source of myoﬁbroblasts in both ﬁbrosis and cancer [21].
Furthermore, CAFs may arise directly from carcinoma
cells through EMT [3, 7], allowing cancer cells to adopt
a mesenchymal cell phenotype, with enhanced migratory
capacity and invasiveness [22]. Indeed, mainly in breast
cancers, have been reported CAF somatic mutations in TP53
and PTEN,a sw e l la sg e n ec o p yn u m b e ra l t e r a t i o na to t h e r
loci in tumour stroma, [23, 24]. Actually, more recently,
Radisky et al. [25], demonstrated that treatment of mouse
mammary epithelial cells with MMP3 cause EMT through a
pathways involving elevated ROS production and increased
levels of Rac1b. The ROS increase in cells treated with MMP-
3 was caused by mitochondrial activation and was found to
be required for the induction of the mesenchymal vimentin
as well as other myoﬁbroblast genes. Thus, a new role for
ROS in tumour progression is emerging, in addition to their
well-known action in the oxidative damage to DNA. We
have recently demonstrated that CAFs secrete MMPs which
in turn stimulate ROS production in prostate carcinoma
cells via a Rac1b/Cox2/HIF-1α pathway, ﬁnally leading to
tumour growth and metastatic spreading [9]. Furthermore,
Toullec et al., using a model of junD-deﬁcient ﬁbroblasts,
demonstrated that the constitutive oxidative stress generated
by inactivation of the junD-gene promotes the conversion
of ﬁbroblasts into myoﬁbroblasts in a HIF1α and CXCL12-
dependent pathway [19].
Mitochondria are the major site of ROS generation,
which occurs mainly at complexes I and III of the respiratory
chain. It is well known that mitochondrial disfunctions
and increased ROS levels are present in many cancer cells.
Pelicano et al. evidentiated a more invasive behavior of
breast cancer cells in which oxidative stress is induced by
inhibition of the electron transport complex I with rotenone
[26]. A correlation between mutations in mitochondrial
genes of complex I and cancer has been observed in
various laboratories [1, 27, 28]. Recently, the group of G.
Romeo reported, in the thyroid oncocytic cell line XTC.UC1,
a dramatically decreased activity of complex I and III
associated with ROS increase. Indeed, these defects are due
to two mtDNA mutations: a frameshift mutation in the
gene encoding ND1 subunit of complex I and a missense
substitution in the cytochrome b gene, which aﬀects the
catalytic site involved in the electron transfer of complex
III [29, 30]. Furthermore, mitochondria dysfunctions in
a tumour cell line contribute to tumour progression by
enhancing the metastatic potential of tumour cells [1].
Indeed, Ishikawa et al. demonstrated, by replacing the6 Journal of Signal Transduction
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(a) Boyden cell invasion assay. Control and mutated ﬁbroblasts were incubated in low glucose serum-free media in normoxic or hypoxic conditions
(1% O2) for 24 hours. Media are then collected, and monolayers of A375 human melanoma cells were incubated in these conditioned media for 24
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randomly chosen ﬁelds. The results are representative of three experiments with similar results ±P< 0.05 media from mutated ﬁbroblasts versus media
from control ﬁbroblasts, ∗P<0.005 media from mutated ﬁbroblasts versus media from control ﬁbroblasts
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(c) Fibroblasts were cultured as in (b) A375 melanoma cells were then
incubated for 24 hours with media collected from ﬁbroblasts. 15 ×
103A375 melanoma cells were seeded into the upper compartment of
Boyden chambers coated with Matrigel. Cells were allowed to migrate
through the ﬁlter toward the lower compartment ﬁlled with complete
medium for 24 hours. Cell invasion was evaluated after Diﬀ-Quick
staining by counting cell in six randomly chosen ﬁelds. The results
are representative of four experiments with similar results. ∗P< 0.005
media from mutated ﬁbroblasts versus media from control ﬁbroblasts
Figure 5: Conditioned media from mutated ﬁbroblasts promotes melanoma cells invasiveness; NAC treatment blocks HIF-1α stabilization
and reverts the increase of melanoma cells invasiveness.Journal of Signal Transduction 7
endogenous mtDNA in a mouse tumour cell line that was
poorly metastatic with mtDNA from a cell line that was
highly metastatic and viceversa, that the recipient tumour
cells acquired the metastatic potential of the transferred
mtDNA. Really, mtDNA containing mutations in the ND6
(NADH dehydrogenase subunit 6) gene and hence a deﬁ-
ciency in respiratory complex I activity triggers an increase
of ROS and higher expression levels of two genes associated
with neoangiogenesis, namely, HIF-1α and VEGF.A sa l r e a d y
mentioned, mitochondrial alterations in cancer cells have
been intensively studied to understand their role in tumour
development and progression [31, 32], but, at least to our
knowledge, this manuscript, for the ﬁrst time, evidenced
that mitochondrial dysfunctions in stromal cells aﬀect the
invasiveness of cancer cells. Indeed, our data show that ROS
produced by mitochondrial dysfunction aﬀect not only the
migratory and invasive abilities of ﬁbroblasts themselves but
also the aggressiveness of melanoma cancer cells. In order
to investigate the involvement of mitochondrial ROS derived
from stromal cells in modulating the invasiveness of tumour
cells, we used ﬁbroblasts producing elevated mitochondrial
ROS due to defects in NADH: ubiquinone oxidoreductase,
or complex I. Dysfunctions of this complex cover more than
30% of hereditary mitochondrial encephalopathies [33–35];
furthermore, complex I defects have been also found in
familiar Parkinson disease [11, 13], hereditary spastic para-
plegia [36], Friedreich ataxia [37], and aging [38, 39]. We
used ﬁbroblasts from a baby diagnosed for Leigh syndrome
(NDUFS4 W15X), from a baby diagnosed for leukodystro-
phy (NDUFS1 Q522K), from a child with complex I deﬁcit
(NDUFS1 R557X/T595A), and from a patient with familiar
Parkinsonsdisease(PINKW437X)inwhichmutationsinthe
ND5andND6 mitochondrialgenesofcomplexIcoexistwith
mutation in the nuclear phosphatase and tensin homolog-
(PTEN-) induced serine/threonine putative kinase-1 (PINK-
1) gene. We showed that in normoxic conditions all muta-
tions present in these ﬁbroblasts, with the exception of
the mutation in the gene NDUFS4, produce an increase
in ROS level, which correlates with the levels of α-SMA
and hence with the degree of diﬀerentiation towards the
myoﬁbroblast-activated form. This diﬀerentiation represents
also a key event during wound healing and tissue repair [4].
The deregulation of normal healing and continued exposure
to chronic injury results in tissue ﬁbrosis, massive deposition
of ECM, scar formation, and organ failure. Indeed, oxidative
stress, caused by increase in ROS is closely associated with
ﬁbrosis [40] and inhibitors of ROS have shown promise
in clinical trials targeting this disease [41–43]. Herein, we
demonstrate that mutated ﬁbroblasts have a great ability
to increase their motility and invasiveness. Overall, these
ﬁndings indicate that increased mitochondrial ROS induce
the transdiﬀerentiation of ﬁbroblasts to their activated form
suggestingapossibleinvolvementofthesemutatedﬁbroblast
also in ﬁbrogenic events.
The inappropriate induction of myoﬁbroblasts that leads
to organ ﬁbrosis greatly enhances the risk of subsequent can-
cer development, by creating a stimulating microenviron-
mentforepithelialtumorcells.Really,weshowthatexposure
of melanoma cells to media of ﬁbroblasts with mitochon-
drial dysfunctions cultured in hypoxic conditions promotes
invasiveness of tumour cells. It is well known that in hypoxic
condition, the low oxygen tension increases the generation
of mitochondrial ROS that prevent hydroxylation of HIF1α
protein, thus resulting in stabilization and activation of its
transcriptional activity [14, 15, 44]. Recently, for instance,
Klimova et al. demonstrated that ROS generated by mito-
chondrial complex III are required for the hypoxic activation
of HIF1α [16]. Furthermore, Brunelle et al. showed that
ﬁbroblasts from a patient with Leigh’s syndrome, which
display residual levels of electron transport activity, stabilize
HIF1α during hypoxia [45]. Really, we evidentiated in
hypoxic conditions an extra ROS production in ﬁbroblasts
carrying mutations in mitochondrial complex I; this increase
in ROS production is also evident in ﬁbroblasts mutated
in the NDUFS4 gene that, conversely, have a low level of
ROS in normoxic condition. The extra ROS production in
hypoxic condition is associated with HIF1α stabilization.
This stabilization is really dependent on mitochondrial
m u t a t i o n ss i n c ei ti sa b s e n ti nc o n t r o lﬁ b r o b l a s t sa n dﬁ n a l l y
leads to the transcriptional activation of genes that allow
cells to adapt to and survive in the hypoxic environment.
WebelievethatthisextraROSproductionactssynergistically
with the hypoxic condition in the promotion of a pro-
invasive behavior of melanoma cancer cells. Neutralizing
this extra ROS production with antioxidants allows the
degradation of HIF1α and abolishes the aggressive behavior
of melanoma cancer cells. Altogether we evidentiated that
mitochondrialROSproducedbycomplexIdefectsofstromal
components, namely, activated ﬁbroblasts, are key molecules
able to modulate the behavior of surrounding cancer cells,
increasing their aggressiveness.
These data underline once again the close loop between
tumor cells and stromal counterparts. It is well known
that activated ﬁbroblasts inﬂuence, through the secretion
of soluble factors, the adhesive and migratory properties of
cancer cells, which then in turn release cytokines inﬂuencing
the behavior of stromal cells. Thus, to deeply explore the
eﬀect of mutated ﬁbroblasts on surrounding tumour cells
we investigated the transcriptional levels of some HIF1α
targetgenesinﬁbroblastsculturedinhypoxicconditions.We
observedanincreaseinVEGF-A,HGF,andSDF1transcripts.
These data are in keeping with those obtained by Orimo
etal.[46],demonstratingthatthecoinjectionoftumourcells
with CAFs into nude mice generates larger xenografts with
respecttothosegeneratedwithnormalﬁbroblasts.Thisevent
correlates with an increase in both cancer-cell proliferation
and angiogenesis through the SDF-1 secretion. In agree-
ment, Toullec et al. demonstrated that the same cytokine
causes the conversion of ﬁbroblasts into highly migrating
myoﬁbroblasts and subsequently promotes migration and
dissemination of neoplastic cells [19]. Furthermore, Cat et
al. showed that myoﬁbroblasts secrete large amounts of HGF
and VEGF resulting in a signiﬁcant increase in the invasive
capacity of surrounding tumor cells [17]. Besides, clinical
studies show that the abundance of stromal myoﬁbroblast
is associated with disease recurrence, as shown for human
colorectal cancers [47]. Really, our data, showing an increase
in ﬁbroblast secreted VEGF-A, HGF, and SDF1, are in8 Journal of Signal Transduction
keeping with others emphasizing that tumour dissemination
could be facilitated by the myoﬁbroblastic component of the
stroma through the secretion of invasion associated-secreted
factors.
Altogether our ﬁndings suggest a possible role of ROS
production, due to mitochondrial complex I dysfunctions of
stroma, in ﬁbroblast activation as well as in cancer progres-
sion and invasion.
4.MaterialsandMethods
4.1. Materials. Unless speciﬁed, all reagents were obtained
from Sigma. Antibodies anti-HIF-1α were from BD Trans-
duction Laboratories; antibodies anti-α-SMA were from
Sigma; antibodies anti-actin were from Santa Cruz Biotech-
nology; MitoSOX Red mitochondrial superoxide indicator
was from Molecular Probes.
4.2. Cell Culture. Control ﬁbroblasts (neonatal human der-
mal ﬁbroblasts) were from Cambrex. Fibroblasts carrying
mitochondrial mutations in the nuclear NDUFS4 gene-
W15X and in the NDUFS1 gene-Q522K (from M. Zeviani,
C. Besta Neurological Institute Foundation, Milan) were cul-
tivated and characterized by S. Scacco. Fibroblasts carrying
mutation in the nuclear PINK1 gene-W437X (from G. De
Michele, Department of Neurological Sciences, Federico II
University, Naples) were cultivated and characterized by A.
M. Sardanelli. Fibroblasts carrying mitochondrial mutations
in the nuclear NDUFS1 gene (NDUFS1 R557X/T595A)
were a generous gift from Fondazione Giuseppe Tomasello
O.N.L.U.S. A375 human melanoma cells were from ATCC.
Cells were cultured in DMEM supplemented with 10%
fetal bovine serum and maintained in 5% CO2 humidiﬁed
atmosphere.
4.3. Mitochondrial Superoxide Detection. 25×103 cells were
cultured for 48 hours in low glucose DMEM medium
(5mM glucose). Cells were then incubated for 10 minutes
at 37◦Cw i t h5 μM MitoSox in PBS. Cells are trypsinized,
centrifuged, washed with PBS, and resuspended in 300μL
PBS. A ﬂowcytometer analysis was then performed (MitoSox
excitation/emission: 510/580nm). For the confocal micro-
scopeanalysisofO2
•− level,cellswereseededontocoverslips,
incubated for 10 minutes at 37◦Cw i t h5 μM MitoSox in
PBS, washed with PBS, and analysed with a laser scanning
confocal microscope (model LEICA TCS SP2 with Acusto-
Optic Beam Splitter) equipped with a ﬁve-lines Ar laser and
two He/Ne lasers (lines 543 and 633nm).
4.4. Western Blot Analysis. 1 × 106 c e l l sw e r el y s e df o r2 0
minutes on ice in 500μL of complete radioimmunoprecipi-
tation assay (RIPA) lysis buﬀer (50mM Tris-HCl (pH 7.5),
150mM NaCl, 1% NP40, 2mM EGTA, 1mM sodium ortho-
vanadate, 1mM phenylmethylsulfonyl ﬂuoride, 10μg/mL
aprotinin, 10μg/mL leupeptin). Lysates were clariﬁed by
centrifuging, separated by SDS-PAGE, and transferred onto
nitrocellulose. The immunoblots were incubated in 3%
bovine serum albumin, 10mM Tris-HCl (pH7.5), 1mM
EDTA, and 0.1% Tween 20 for 1 hour at room temperature
and were probed ﬁrst with speciﬁc antibodies and then with
secondary antibodies.
4.5. Immunohistochemistry. Fibroblasts were seeded onto
coverslips, washed with PBS, and ﬁxed in 3% paraformalde-
hyde for 20 minutes at 4◦C. Fixed cells were permeabilized
with three washes with TBST (50mM Tris/HCl pH 7.4,
150mM NaCl, 0.1% Triton X-100) and then blocked with
5.5% horse serum in TBST for 1 hour at room temperature.
Cells were incubated with primary antibody, 1:100 dilution
in TBS (50mM Tris/HCl pH 7.4, 150mM NaCl) containing
3% BSA overnight at 4◦C. After extensive washes in TBST,
cells were incubated with secondary antibodies for 1 hour
at room temperature, washed, and mounted with glycerol
plastine. Finally, cells were observed under a laser scanning
confocal microscope (model LEICA TCS SP2 with Acusto-
Optic Beam Splitter) equipped with a ﬁve-lines Ar laser and
two He/Ne lasers (lines 543 and 633nm).
4.6. Preparation of Conditioned Media. Conditioned media
were obtained from ﬁbroblasts as follow: ﬁbroblasts were
incubated in low glucose (5mM glucose) serum-free media
in normoxic or hypoxic conditions (1% O2) for 24 hours.
Media are then collected and monolayers of A375 human
melanoma cells were incubated in these conditioned media
for 24 hours.
4.7. In Vitro Boyden Migration and Invasion Assay. Fibrob-
lasts were serum starved for 24 hours and then 15×103
cells were seeded onto Boyden chamber (8mm pore size,
6.5mm diameter) for the migration assay. For the invasion
assay Boyden chambers are precoated with Matrigel (12.5μg
Matrigel/ﬁlter).Inthelowerchamber,completemediumwas
addedaschemoattractant.Following24hoursofincubation,
the inserts were removed and the noninvading cells on the
upper surface were removed with a cotton swab. The ﬁlters
were then stained using the Diﬀ-Quik kit (BD Biosciences)
and photographs of randomly chosen ﬁelds are taken.
4.8. Real-Time PCR. Total RNA from ﬁbroblasts was ex-
tracted using RNeasy (Qiagen) according to the manufac-
turer instructions. Strands of cDNA were synthesized using
a high-capacity cDNA reverse transcription kit (Applied
Biosystem) using 1μg of total RNA. For quantiﬁcation of
VEGF-A, SDF-1, and HGF mRNA, real-time PCR, using
Power SYBR green dye (Applied Biosystem) was done on
a 7500 fast real-time PCR system (Applied Biosystem).
The primers for VEGF-A were 5 TTCTGCTGTCTTGGG
TGCAT-3  (forward) and 5 TGTCCACCAGGGTCTCGATT-
3  (reverse). The primers for SDF-1 were 5 GTGTCACTG
GCGACACGTAG-3  (forward) and 5 TCCCATCCCACA
GAGAGAAG-3  (reverse). The primers for HGF were 5 CAT
CAAATGTCAGCCCTGGAGTT-3  (forward) and 5 CCT
GTAGGTCTTTACCCCGATAGC-3  (reverse). Data are nor-
malised to those obtained with glyceraldehyde-3-phosphate
dehydrogenase primers. Results (mean ± SD) are the mean
of three diﬀerent experiments.Journal of Signal Transduction 9
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